method for the analysis of amphetamines in blood and urine was developed and validated. Chromatographic separation was achieved on a Nucleodur ® Sphinx RP column with an LC gradient (a mixture of 10 mM ammonium formate buffer and acetonitrile), ensuring the elution of amphetamine, methamphetamine, MDMA, MDA, MDEA, PMA, and ephedrine within 11 min. The method was fully validated, according to international guidelines, using only 100 and 50 μL of blood and urine, respectively. The method showed an excellent intra-and interassay precision [relative standard deviation (RSD) < 11.2% and bias < 13%] for two external quality control samples (QC) for both matrices and three and two 'in house' QCs for blood and urine, respectively. Responses were linear over the investigated range (r 2 > 0.99, 2.5-400 μg/L for blood and 25-1000 μg/L for urine). Limits of quantification were determined to be 2.5 and 25 μg/L for blood and urine, respectively. Limits of detection ranged from 0.05 to 0.5 μg/L for blood and 0.25 to 2.5 μg/L for urine, depending on the compound. Furthermore, the analytes and the processed samples were demonstrated to be stable (in the autosampler for at least 72 h and after three freeze/thaw cycles), and no disturbing matrix effects were observed for all compounds. Moreover, no carryover was observed after the analysis of high concentration samples (15,000 μg/L). The method was subsequently applied to authentic blood and urine samples obtained from forensic cases, which covered a broad range of concentrations. The validation results and actual sample analyses demonstrated that this method is rugged, precise, accurate, and well-suited for routine analysis as more than 72 samples are analyzed non-stop in 24 h with minimum sample handling. The combination of the high-throughput online SPE and the well-known sensitivity and selectivity assured by MS-MS resulted in the elimination of the bottleneck associated with the sample preparation requirements and provided increased sensitivity, accuracy, and precision.
Introduction
Amphetamine is a psychostimulant drug known to produce wakefulness and increase focus and appetite. The main effects reported after use of amphetamines are euphoria, increased energy, muscle tremor, hypertension, increased blood temperature, and dry mouth (1) . Designer amphetamines chemically related to amphetamine include methamphetamine, methylenedioxyamphetamine (MDA), methylendioxymethamphetamine (MDMA), methylenedioxyethylamphetamine (MDEA), and 4-methoxyamphetamine (PMA). They also present similarities to some naturally occurring weak stimulants such as ephedrine.
Globally, after cannabis, amphetamines are among the most commonly consumed illicit drugs. According to the annual report of the European Monitoring Center for Drugs and Drug Addiction (EMCDDA), surveys conducted in the European countries in recent years showed an increase in amphetamine and ecstasy consumption (2) . Methamphetamine use was not observed in Belgium but was reported in other countries (e.g., U.S., Lithuania, Slovenia, Russia, and Poland).
Several techniques have been used for the toxicological analysis of amphetamines in blood and/or urine including gas chromatography with mass spectrometry (GC-MS) (3, 4) and liquid chromatography with tandem mass spectrometry (LC-MS-MS) (5) (6) (7) (8) (9) (10) . With the advent of increased selectivity when using LC-MS-MS, the possibility of omitting the sample preparation step arose (11) (12) (13) because sample preparation is considered the main bottleneck as it is often time consuming. Therefore, several clinical and forensic laboratories simply use direct injection of the biological sample. However, sample preparation is often required to reduce matrix effects. The increased demand for high-throughput causes a unique situation of balancing cost versus analysis speed. An elegant system for the rapid analysis of complex samples can be obtained by online coupling of solid-phase extraction (SPE) to LC-MS detection. With this procedure, the sample is injected directly into the SPE-MS system, and the rate-limiting off-line extrac-tion step is eliminated. As a result, automation leads to higher sample throughput, and increased sensitivity as the whole sample extract is analyzed and not a fraction. Other advantages are safer sample handling and improved precision as operator intervention is minimized (14, 15) . Several generic approaches have recently been developed for online sample extraction coupled to LC-MS (15) (16) (17) (18) (19) (20) (21) .
Wu et al. (22) developed a method for the direct analysis of amphetamines for urine by column-switching connecting a SPE column before the analytical column. However, the method was not completely validated because no studies of matrix effects and carryover were carried out. According to the literature, when extractions are performed using automated liquid handlers, the potential of carryover and cross-contamination increases (23) . Thus, it must be included in method validation.
The aim of this study was to develop and completely validate a new simple, rugged, and high-throughput online SPE-LC-MS-MS method for rapid and simultaneous analysis of amphetamine, methamphetamine, MDMA, MDA, MDEA, PMA, and ephedrine in blood and urine. This online SPE-LC-MS method offers the entire process of conditioning, sample application, washing, and elution taking place at constant flow rates. Another important advantage is that no manual transfers are made and that the whole extracted sample is loaded onto the LC column without the need for a preconcentration step. Disposable cartridges were applied for each injection minimizing the carryover. The method was fully validated with respect to precision, accuracy, quantification and detection limit, stability, sample throughput, and carryover.
Materials and methods

Reagents
Individual stock solutions of amphetamine, methamphetamine, MDA, MDMA, and PMA (all certified at a concentration of 1 mg/mL in methanol), and the internal standards (IS) [ ephedrine (ephedrine-d 3 ) (certified concentration at 0.1 mg/mL in methanol) were from LGC Promochem (Molsheim, France). HPLC-grade water, LC-MS-grade methanol, UPLC-MS-grade 0.1% formic acid in water, and LC-MS-grade acetonitrile were purchased from Biosolve (Valskenswaard, The Netherlands). Ammonia solution (32%, extra pure) was from Merck (Darmstadt, Germany). Ammonium formate (99.995+% powder) and triethylamine (puriss.p.a.) were purchased from Sigma Aldrich (Steinheim, Germany). Oasis HLB Prospekt cartridges were from Waters (Milford, MA). External quality control (QC) blood samples were obtained from Medichem World (Steinenbronn, Germany). Liquichek external quality controls C1 and C3 for urine were purchased from Bio-Rad Laboratories (Irvine, CA). The concentrations of the amphetamines in these external QCs are displayed in Table I (for blood) and Table II (for urine) as 'nominal value'.
Specimens
Pooled blank blood samples were used for development and validation of the procedure and were obtained from a local blood bank whereas drug-free volunteers provided blank urine.
Authentic blood and urine samples were obtained from forensic cases or from 28 volunteers who received either placebo or a dose of MDMA (75 mg). Blood samples were freshly collected 1 h and 15 min after ingestion, and the venotubes (without anticoagulant) were directly centrifuged for 10 min at 3000 rpm. The serum obtained was stored at -20°C prior to analysis. The study protocol was approved by the ethics committee of the University Hospital of Maastricht in the Netherlands.
Preparation of standard solutions
Two different working solutions of the non-deuterated compounds at 4 mg/L in methanol were prepared. The first was used for preparation of the calibrators and the second for the 'in house' QC samples. The internal standard (IS) working solution of 1 mg/L was prepared in methanol. Working solutions were prepared monthly and stored at 4°C. The 'in house' QCs were stored at -20°C until use. The external QCs were prepared following the indications of the manufacturer.
To obtain the lower concentrations needed for internal standardization and validation of each experiment, further dilutions in water were prepared the same day.
SPE-LC-MS-MS Sample preparation: XLC (online SPE)
Sample extraction was performed using the online SPE Symbiosis TM Pharma System (Spark Holland TM , Emmen, the Netherlands). It comprises two integrated units: the Reliance TM autosampler with two integrated binary LC pumps and the online SPE unit Prospekt-2 system, which includes the automated cartridge exchange (ACE) unit and two high-pressure dispensers. The entire system was operated by SparkLink for Masslynx™ software version 4.1 (Waters, Milford, MA). The extraction procedure was carried out in glass screw-neck vials of high-quality Waters glassware.
Initially, 10 SPE cartridges were evaluated to determine the optimal SPE sorbent for the extraction of all analytes. The evaluated cartridges were HySphere CN, C2, C8, C8EC, C18, Resin SH, and Resin GP (SparkHolland) and Oasis HLB, MCX, MAX cartridges (Waters). The solvents used for the SPE procedure were thoroughly investigated to determine the optimal combination to maximize recovery of the analytes of interest while eliminating carryover and elution of any endogenous components causing matrix effects.
Nine hundred and fifty microliters of ammonium formate buffer (10 mM) and 50 μL of the IS working solution (0.1 mg/L) were added to 100 μL of blood and 50 μL of urine, respectively. The following XLC program was subsequently used: after conditioning with 2 mL of methanol, 1 mL of water and 1 mL of water (5% NH 4 OH), 150 μL of the diluted blood or urine sample was applied onto the SPE cartridge using 1.5 mL of water (5% NH 4 OH) as transport solvent. Clean-up was accomplished with 1 mL washes of 5% NH 4 OH and water in order to remove salts and endogenous interferences present in the biological samples. The cartridge was then physically moved with a robotic arm to the elution (right) clamp in line with the LC pumps, thus leaving the extraction (left) clamp ready to start with a new sample. While the elution step was being performed, a new cartridge was conditioned, loaded, and washed in the left clamp. The elution was performed with the LC gradient of the mobile phase [ammonium formate buffer 10 mM (A) and acetonitrile (B)] [standard (gradient pump) elution mode] during the whole chromatographic run. Following the elution step, several automated clamp and valve washes with water, acetonitrile, and 0.2% triethylamine were carried out to avoid contamination between samples.
Chromatographic conditions. Several C 18 analytical columns (XBridge, Waters), SunFire (Waters), Gemini (Phenomenex, Torrance, CA), Chromolith (Merck, Whitehouse Station, NJ) and Nucleodur Sphinx (Macherey-Nagel, Dueren, Germany) were initially evaluated in terms of chromatographic retention, peak shape, and carryover. The Nucleodur Sphinx RP column (3 μm, 120 × 2 mm) (FilterService, Eupen, Belgium) was finally chosen. A gradient was performed starting from 30% B and a flow rate of 0.25 mL/min for 3 min. From 3 to 8 min, B was subsequently increased to 35%. Then, from 8 to 9 min, B was linearly increased to 95% and kept for 1.5 min before returning to the initial conditions. Before the next injection, the column was equilibrated for 9.5 min to assure the appropriate initial conditions of the gradient for the next injection.
Tandem MS. A Quattro Premier tandem MS (Waters) was applied. Ionization was achieved using electrospray in positive ionization mode (ESI + ). Nitrogen was used as nebulization and desolvation gas at a flow rate of 600 L/h and heated to 350°C. Capillary voltage and source block temperature were 1 kV and 120°C, respectively.
In order to establish the appropriate multiple reaction monitoring (MRM) conditions for the individual compounds, solutions of standards [200 μg/L, in 10 mM ammonium formate/acetonitrile (50:50, v/v)] were infused into the MS, and the cone voltage (CV) was optimized to maximize the intensity of the protonated molecular species [M + H] + . Collision-induced dissociation (CID) of each proto- nated molecule was performed. The collision gas (argon) pressure was maintained at 0.35 Pa (3.5 × 10 -3 mBar) and the collision energy (eV) adjusted to optimize the signal for the most abundant product ions, which were subsequently used for MRM analysis.
Online SPE-LC-MS-MS assay validation
Validation was performed based on the FDA guidelines and recent publications concerning validation of bioanalytical methods (24, 25) .
Linearity, limit of quantification (LOQ), limit of detection (LOD), precision, and accuracy (bias)
Quantification was performed by integration of the area under the specific MRM chromatograms in reference to the integrated area of the deuterated analogues. Freshly prepared working solutions at 4000 μg/L were used to prepare blood calibrators at concentrations of 400, 200, 100, 50, 25, 12.5, 5, and 2.5 μg/L for blood and at 1000, 800, 500, 250, 200, 125, 100, 50, and 25 μg/L for urine. Standard curves, freshly prepared with each batch of QC samples and authentic samples, were generated using a least-squares linear regression with a 1/x-weighing factor for all compounds.
The LOQ was estimated by replicate analysis (n = 2) over eight different days and was defined as the concentration of the lowest calibrator that was calculated within ±20% of the nominal value and with a relative standard deviation (RSD) of less than 20%. The LOQ was calculated performing the analysis of variance: a 'single factor' ANOVA test [significance level (α) of 0.05].
The LOD was estimated from blank blood and urine samples, spiked with decreasing concentrations of the analytes. It was defined as the concentration where the response of the qualitative ion could reliably be differentiated from background noise [i.e., signal-to-noise ratio (S/N) equal to or greater than 3:1]. The acceptance criteria for ion ratios should be equal to or lower than 20% and retention time deviations lower than 3.5% relative to that of the corresponding control or calibrator.
Five QCs were analyzed for blood: two external QCs (Medichem) and three in house QCs. For urine, four QCs were monitored: two external from Bio-rad and two in house. The in house QCs were prepared by different operators from different working solutions different of those for the calibrators and stored at -20°C until use. Intraassay and interassay precision was evaluated by replicate (n = 2) analysis of the QC samples performed over eight different days. Precision (expressed as %RSD r for intraassay precision and %RSD t for interassay precision) was determined by performing the analysis of variance: a single factor ANOVA test [significance level (α) of 0.05]. Comparing the mean of calculated concentrations of QC samples to their respective nominal values, provided data on the accuracy of the method.
Selectivity
The selectivity of the method was verified by examination of the chromatograms obtained after the extraction of eight different blank blood and urine samples from different origins.
Moreover, a blank urine and blood sample spiked with morphine, codeine, benzoylecgonine, codeine, 6-MAM, fentanyl, pholcodine, hydromorphone, hydrocodone, norcodeine, dihydrocodeine, oxycodone, oxymorphone, cocaine, methadone, EDDP, 27 benzodiazepines, zolpidem, zopiclone, zaleplon, THC, 11-OH-THC, and THC-COOH were also analyzed to check for interferences.
Stability in the autosampler and after three freeze/thaw cycles
The autosampler stability of diluted samples at concentrations of 160 and 3.5 μg/L for blood and 400 or 80 μg/L in urine (n = 6 at each concentration) were monitored as follows: one pool of samples were determined immediately and another pool of samples were analyzed after remaining in the autosampler at 6 ± 2°C for 24 and 72 h (a weekend). All samples were spiked with the IS just before analysis.
Stability studies of amphetamines after three freeze/thaw cycles in both matrices were determined through spiked blank urine and blood samples with concentrations of 160 and 3.5 μg/L for blood and 400 or 80 μg/L in urine (n = 6 at each concentration).
All the stability experiments were tested against a lower percentage limit corresponding to 90-110% of the ratio (mean value of stability samples/mean value control samples) with a 90% confidence interval of the stability samples between 80 and 120% of the mean of the control samples.
Assessment of matrix effects
To assess any potential suppression or enhancement of ionization due to the sample matrix, two different analyses were carried out. The first one involved a postcolumn infusion experiment (26) . This experiment is based on a continuous postcolumn infusion of a mixture of the analytes and their internal standards (10 μg/L at a flow rate of 10 μL/min) to produce a constant elevated response in the MRM channels. This constant response was monitored throughout the whole run following the injection of urine and blood samples from different origin (n = 6) and compared to the response following the injection of mobile phase only.
The second experiment consisted of a comparison between the peak responses of the analytes of interest spiked into blank blood (160 and 3.5 μg/L) or urine (400 and 800 μL) (n = 3 for each concentration) and those obtained after being spiked in the mobile phase at the same concentration levels (27) .
Recovery
Extraction recoveries were estimated by performing the following experiments: a blank sample spiked at 160 and 3.5 μg/L (and the IS to each concentration) for blood and 400 and 80 μg/L (and the IS to each concentration) for urine (n = 3 for each concentration) were loaded and washed in a first SPE cartridge while a second cartridge was placed in series to determine the breakthrough of the first one (breakthrough is the maximum volume from which 100% recovery can be achieved). Both cartridges where subsequently eluted independently. Recovery was considered to be the ratio between the response obtained after elution of the first cartridge and the total response (sum of both the first and second SPE cartridge).
Carryover
Carryover was evaluated by the analysis of blank blood and urine samples spiked with the IS after the analysis of the upper calibrator (n = 8) for both matrices and after the analysis of a very concentrated urine sample (n = 3) (15,000 μg/L).
Results and Discussion
During optimization of the SPE, the Oasis MCX, C 18 , and HLB cartridges demonstrated excellent recovery for all analytes of interest. HLB cartridges were the best choice because of optimal analyte elution from the MCX, an extremely high pH was required, which was not compatible with the chosen analytical column. The HLB cartridge is a macroporous polimer made of a balanced ratio of two monomers, the lipophilic divinylbenzene and the hydrophilic N-vinylpyrrolidone.
The applied gradient ensured the elution of all the drugs examined within 11 min and produced chromatographic peaks of acceptable symmetry.
The method was validated for selectivity, linearity, LOQ, LOD, precision, accuracy, matrix effect, recovery, stability, and carryover by the analysis of spiked blood and urine samples.
Selectivity of the method was achieved by a combination of retention time, precursor, and two product ions. The most prominent precursor-product transitions were used for quantification and the next most abundant used as qualifier (Table  III) . For the corresponding deuterated analogues, only one transition was monitored. Injection of single analyte solutions did not produce interference in the other MRM channels. No interferences were observed after the analysis of blank urine samples spiked with several overthe-counter drugs, ensuring the selectivity of the method. The ion ratios quantifier versus qualifier were as follows: amphetamine 2.5, methamphetamine 2.9, MDA 2.2, MDMA 1.4, MDEA 1.5, PMA 1.0, and ephedrine 5.6.
The quantification range applied was 2.5-400 μg/L for blood and 25-1000 μg/L for urine. Correlation coefficients of the weighed (1/x) linear regressions for this range were higher than r 2 = 0.99. Figure 1 shows the MRM chromatograms obtained following the analysis of the blood lowest calibrator (2.5 μg/L). At this concentration a S/N >10:1 was observed for the qualifier, and the criteria for LOQ were satisfied. LOD ranged from 0.05 μg/L to 0.5 μg/L for blood and 0.25 μg/L to 2.5 μg/L for urine, depending on the compound. The intra-and interassay precision * Data represent the mean of six experiments at two concentration levels (n = 3) for both matrices; blood (n = 3) at 160 and 3.5 μg/L; urine (n = 3) at 400 and 80 μg/L. 8
were satisfactory with all RSDs lower than 12% (Table I and II for blood and urine, respectively). Results indicated that the bias of the assay was < 13%. Post-column infusion experiments were performed to provide information of the matrix effect throughout the course of the elution time for the analytes. A second experiment was carried out where peak responses obtained when the compounds were spiked to a blank blood and urine samples were compared with the response obtained when the compounds were added to a mobile phase only at the same concentration. In both experiments, no matrix effects were observed except for MDEA. For MDEA some ion suppression was observed for blood (-31.3%); nevertheless, the use of deuterated IS partially compensates for the observed matrix effect, and thus, it did not compromise the quantification as demonstrated with the results obtained for the intra-and interassay precision (28) . The results of the matrix effects and recovery at the two different concentrations are presented in Table IV . Very high and reproducible recoveries were obtained with this online SPE procedure for all analytes. The stability of samples in the autosampler after 24 h and 72 h and after three freeze/thaw cycles were monitored. No compound presented instability during this period of time.
After optimization of the method, no carryover was observed in the analysis of a blank sample injected after the analysis of the upper calibrator (neither with blood nor urine). No significant carryover was observed after the analysis of a blank urine sample analyzed after the injection a very high concentrated authentic urine sample (15,000 μg/L) ( Figure 2 ). In addition, during analyses of authentic urine samples (n = 50) from forensic and toxicology cases, a blank was injected after each sample to check for carryover.
Samples
Blood samples were collected from 28 healthy volunteers 1 h and 15 min after the ingestion of a single dose of MDMA (75 mg) or a placebo. The blood samples were centrifuged for 10 min at 3000 rpm, and the serum obtained was stored at -20°C prior to analysis. The results are presented in Table V . Concentrations of MDMA were generally low. The median and minimummaximum range (in μg/L) for MDMA were 48.3 (919.7-77.00). The concentrations of the authentic urine samples varied considerably. Those urine samples with concentrations higher than the upper calibrator (1000 μg/L) were diluted 1:10 and reanalyzed. Figure 3 shows the MRM chromatogram of the analysis of a urine sample from an amphetamine user.
Conclusions
LC-MS-MS offers high specificity, good precision and accuracy, a wide dy- namic range, and high sensitivity. Due to its mass selectivity, it was expected that method development time and sample turnover time would be reduced significantly. However, ionsuppresion requires that the majority of biological matrix constituents are removed prior to LC-MS-MS analysis making sample preparation a time consuming element in the development of LC-MS-MS bioassays. During the process of method development the demands on sensitivity, precision and accuracy become more stringent, which resulted in increasing assay development time (ranging from day 1 for 'quick and dirty' work up to several weeks for a fully validated assay applicable for pre-clinical study samples). Especially, for clinical studies, high demands on specificity, accuracy, and precision must be complied. Apart from full automation, state-of-the-art online SPE provides high precision and sensitivity and a higher sample throughput as compared to liquid liquid extraction (LLE) or off-line SPE (21) . In this article, a fully validated and highly sensitive LC-MS-MS method is described for the simultaneous analysis of the main amphetamines in blood and urine. The method combined online SPE with LC-MS-MS and provided a thorough clean-up of the matrix in combination with high recovery, excellent precision, and accuracy in the linear range investigated using just 100 μL and 50 μL of blood and urine samples. The method was successfully applied to authentic samples from drug users and sensitive enough to detect a single use of MDMA in healthy volunteers. This method is certainly of interest on the field of forensic toxicology.
